Testosterone Undecanoate

Known safety concerns, contraindications, and age-stratified risk factors.

Immediate Effects (4)

Long-Term Risks (4)

Sourcing Dangers (3)

Contraindications (6)

Prostate or Breast Carcinoma

Absolute contraindication. Exogenous testosterone may stimulate androgen-dependent tumour growth.

Monitor

Women and Pregnancy

Absolute contraindication (Category X). Risk of virilisation and fetal abnormalities.

Monitor

Uncontrolled Hypertension

TU formulations, particularly oral versions, cause measurable BP elevation (3 to 5 mmHg for Jatenzo). Uncontrolled hypertension increases risk of cardiovascular events during therapy.

Monitor

Renal or Hepatic Disease

Risk of worsening edema or organ dysfunction. TRAVERSE trial identified AKI signal (2.3% vs 1.5% placebo).

Monitor

Anticoagulant Therapy (Warfarin)

TU potentiates warfarin, requiring frequent INR monitoring and potential dose adjustment of the anticoagulant.

Monitor

Insulin or Anti-Diabetic Therapy

TU increases insulin sensitivity, which may require lowering anti-diabetic medication doses to prevent hypoglycaemia.

Monitor

Auto-Generated Safety Flags

Injectable TU (Aveed) requires a mandatory 30-minute post-injection clinical observation period under a REMS program due to the risk of Pulmonary Oil Microembolism.

Hematocrit levels exceeding 54% during TU therapy require dose reduction or cessation to minimise thromboembolic risk.

Oral TU (Jatenzo) must be taken with a fat-containing meal for reliable lymphatic absorption. Without dietary fat, serum levels may be sub-therapeutic.

FDA-approved labelling for Aveed and Jatenzo explicitly states that safety and efficacy for age-related hypogonadism have not been established.

Administration of exogenous testosterone in males under 25 carries a high-confidence risk of premature epiphyseal closure and potential disruption of neurodevelopmental brain maturation.

Continue